Conditions: Cardiovascular Diseases Heart Diseases
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 905
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the effects of a drug known as CS-747 (also known as prasugrel) on subjects having a procedure called a percutaneous coronary intervention (also referred to as PCI) in which a doctor will attempt to open a blocked vessel (or vessels) in the heart using a catheter (a long thin tube) that has a small balloon on the end. In many cases, patients who have this procedure receive a stent, a small wire spring that helps keep the vessel open.

Detailed description:

Arms:
arm 1: Prasugrel (CS-747) 40 mg oral loading dose (LD) at time of percutaneous coronary intervention (PCI) followed by 7.5 mg oral maintenance dose (MD), once daily, for 29-34 days arm 2: Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 10 mg oral maintenance dose (MD), once daily, for 29-34 days arm 3: Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 15 mg oral maintenance dose (MD), once daily, for 29-34 days arm 4: Clopidogrel 300 mg oral LD at time of PCI followed by an oral 75 mg MD; taken once a day.

Interventions: intervention 1: Prasugrel (CS-747) intervention 2: Clopidogrel
Intervention descriptions: intervention 1: Administered orally intervention 2: Administered orally

Protocol document: